Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market – Industry Trends and Forecast to 2029

Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Analysis and Insights

Gamma-aminobutyric acid (GABA) receptor agonist market has been growing significantly across the globe. The market is expected to show an increased growth rate post COVID-19 as there are surging cases of the neurodegenerative disorders across he regions which will further boost the adoption of gamma-aminobutyric acid (GABA) receptor agonist.

• Data Bridge Market Research analyses that the gamma-aminobutyric acid (GABA) receptor agonist market will grow at a CAGR of 8.2% during the forecast period of 2022 to 2029.

Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Definition

Gamma-aminobutyric acid (GABA) receptor agonist drugs are a type of sedative drug that mimics the activity of the neurotransmitter receptors known as gamma-aminobutyric acid (GABA) receptors found in the mammalian brain. They are used to treat a variety of CNS disorders.

Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Dynamics

Drivers

• Growing Cases of Neurodegenerative Disorders

The rise in the neurodegenerative disorders such as the Alzheimer’s disease and Parkinson’s disease across the globe will result in the expansion of the growth rate of the market. Moreover, the vulnerable aging population is expected to expand the market’s growth within the forecasted period.

Moreover, the adoption of unhealthy lifestyle that increases the risk of evolving mental health disorders are also the growth determinants which bolster the growth of the market. Also, the availability of the treatment will further enhance the growth of gamma-aminobutyric acid (GABA) receptor agonist market.

Furthermore, development in advanced therapy areas, rise in health care spending and the advancement in medical technology will expand the gamma-aminobutyric acid (GABA) receptor agonist market. Additionally, the strong pipeline of upcoming molecules and a favorable reimbursement scenario result in the expansion of gamma-aminobutyric acid (GABA) receptor agonist market.

Opportunities

Moreover, the rise in the research and development activities and increasing investments will boost new opportunities for the market's growth rate.

Furthermore, the increased funding by government and private organizations across emerging economies for treatment of neurological disorders will provide beneficial opportunities for the gamma-aminobutyric acid (GABA) receptor agonist market in the forecast period of 2022-2029. Also, increased surveys, studies and awareness programs will escalate the growth rate gamma-aminobutyric acid (GABA) receptor agonist market in future.

Restraints/Challenges Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market

However, the patent expiration of branded drugs will impede the growth rate of gamma-aminobutyric acid (GABA) receptor agonist market. Additionally, the availability of generic drugs will hinder the gamma-aminobutyric acid (GABA) receptor agonist market growth. The lack of effective treatment options in the market will further challenge the market in the forecast period mentioned above.

This gamma-aminobutyric acid (GABA) receptor agonist market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on gamma-aminobutyric acid (GABA) receptor agonist market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The gamma-aminobutyric acid (GABA) receptor agonist has sedative effects, but it can also have anxiolytic, anticonvulsant, and muscle relaxant effects. Around 50 million people worldwide were diagnosed with Alzheimer's disease which is of the most prevalent neurodegenerative disease, with 5.8 cases in the U.S alone.

Gamma-aminobutyric acid (GABA) receptor agonist market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Covid-19 Impact on Gamma-aminobutyric Acid (GABA) Receptor Agonist Market

The sudden emergence of the COVID-19 has negatively affected the market as it prompted the implementation of strict lockdowns and isolation regulations across the globe which complicated the disease management and medication adherence and even further caused delays in the import and export of drugs and medicines. The lack of access to health-care facilities for routine treatment and medication administration due to social distancing regulations will further affect the market.

Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Scope

The gamma-aminobutyric acid (GABA) receptor agonist market is segmented on the basis of indication, drugs, therapeutics, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Insomnia
• Epilepsy
• Spasticity
• Anxiety
• Others

On the basis of indication, the gamma-aminobutyric acid (GABA) receptor agonist market is segmented into insomnia, epilepsy, spasticity, anxiety and others.

Drugs

• Zolpidem
• Topiramate
• Baclofen
• Others

On the basis of drugs, the gamma-aminobutyric acid (GABA) receptor agonist market is segmented into zolpidem, topiramate, baclofen and others.

Therapeutics

• Bamaluzole
• Phenibut
• Baclofen
• Gaboxadol

On the basis of therapeutics, the gamma-aminobutyric acid (GABA) receptor agonist market is segmented into bamaluzole, phenibut, baclofen and gaboxadol.

Route of Administration

• Oral
• Parenteral
• Intrathecal
• Others

On the basis of route of administration, the gamma-aminobutyric acid (GABA) receptor agonist market is segmented into oral, parenteral, intrathecal and others.

End Users

• Hospitals
• Specialty Clinics
• Others

On the basis of end users, the gamma-aminobutyric acid (GABA) receptor agonist market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

The gamma-aminobutyric acid (GABA) receptor agonist market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Regional Analysis/Insights

The gamma-aminobutyric acid (GABA) receptor agonist market is analysed and market size insights and trends are provided by country, indication, drugs, therapeutics, route of administration, end users and distribution channel as referenced above.

The countries covered in the gamma-aminobutyric acid (GABA) receptor agonist market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the gamma-aminobutyric acid (GABA) receptor agonist market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to due to high prevalence cases of CNS disorders and number of FDA approval drugs in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the focus of various global companies to expand their products in this particular region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Share Analysis

The gamma-aminobutyric acid (GABA) receptor agonist market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gamma-aminobutyric acid (GABA) receptor agonist market.

Some of the major players operating in the gamma-aminobutyric acid (GABA) receptor agonist market are Sanofi, Mylan N.V., Teva Pharmaceutical Industries Ltd, Novartis AG, Aytu BioScience, Inc., Dr. Reddy’s Laboratories Ltd, Endo Pharmaceuticals Inc., Lupin, Johnson & Johnson Services, Inc, Lannett, Sun Pharmaceutical Industries Ltd, Cipla Inc, Aurobindo Pharma and Zydus Cadila among others.

Research Methodology : Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis.

To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-gaba-receptor-agonist-market

SKU-52387